8-K: Lifecore Biomedical Reports Q3 Fiscal 2025 Results, Reaffirms Full-Year Guidance

Lifecore Biomedical announces its Q3 fiscal 2025 financial results, highlighting revenue of $35.2 million and reaffirming its full-year revenue and Adjusted EBITDA guidance.

Summary

• Lifecore Biomedical reported revenues of $35.2 million for the third quarter of fiscal 2025, a 2% decrease compared to the same period last year.
• The decrease in revenue was primarily due to a $1.5 million decrease in CDMO revenues.
• HA manufacturing revenues increased by $1.0 million due to increased demand.
• Gross profit for the quarter was $9.8 million, compared to $11.9 million in the prior year.
• The company recorded a net loss of $14.8 million, or $0.47 per diluted share, compared to a net income of $15.6 million, or $0.42 per diluted share, for the same period last year.
• Adjusted EBITDA for the quarter was $5.7 million, a decrease of $0.7 million compared to the prior year period.
• For the first nine months of fiscal 2025, revenues were $92.4 million, a 2% increase compared to the prior year period.
• The company recorded a net loss of $37.6 million, or $1.24 per diluted share, for the first nine months of fiscal 2025.
• Adjusted EBITDA for the first nine months of fiscal 2025 was $10.4 million, a $0.6 million increase from the prior year period.
• Lifecore is reiterating its full fiscal year 2025 guidance and expects revenue to be approximately $126.5 to $130 million and Adjusted EBITDA to be in the range of $19 to $21 million.
• The company signed multiple new agreements with both new and existing customers during the third quarter.
• Lifecore strengthened its balance sheet through the sale of excess capital equipment, raising approximately $17.0 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company highlights new agreements and the sale of equipment, the financial results show a decrease in revenue and a net loss. The reiteration of full-year guidance provides some stability, but the overall picture is mixed.

Positives

• Lifecore signed multiple new agreements with both new and existing customers, indicating continued demand for its services.
• The sale of excess capital equipment generated $17.0 million, strengthening the company's balance sheet.
• HA manufacturing revenues increased by $1.0 million due to increased demand, showing growth in this segment.
• The company is actively continuing to look for opportunities to reduce operational expenses, facilitate a performance-driven culture, and strengthen its recognized commitment to quality.
• The company reiterated its financial guidance and expects revenue to be approximately $126.5 to $130 million and Adjusted EBITDA to be in the range of $19 to $21 million.

Negatives

• Revenues for the third quarter decreased by 2% compared to the same period last year, primarily due to a decrease in CDMO revenues.
• Gross profit for the quarter decreased due to a decrease in CDMO gross profit and a customer termination resulting in write-off of inventory and equipment.
• The company recorded a net loss of $14.8 million for the quarter, compared to a net income in the same period last year.
• Selling, general and administrative expenses increased due to an increase in stock based compensation and legal expenses related to legacy matters.
• Interest expense increased due to the growth in principal under the Alcon term loans and a reduction in capitalized interest related to the sale of the isolator filler.

Risks

• The company's future performance is subject to various risks and uncertainties, including government regulations, timing of regulatory approvals, and the ability to attract demand for its services.
• The company's ability to meet its financial goals depends on factors such as customer relationships, market conditions, and access to capital.
• The company's financial results are subject to fluctuations in foreign currency exchange rates and global trade tensions.
• The company's forward-looking statements are based on current expectations and are inherently uncertain.

Future Outlook

Lifecore reiterates its full fiscal year 2025 guidance, expecting revenue between $126.5 and $130 million and Adjusted EBITDA between $19 and $21 million.

Management Comments

• Paul Josephs, president and chief executive officer of Lifecore, stated that Lifecore is stronger financially and its manufacturing pipeline is more developed than at any point in the company's recent history.
• Paul Josephs, president and chief executive officer of Lifecore, stated that the company is excited to build on this momentum that they believe will position them well to achieve sustainable profitability in the not too distant future.

Industry Context

Lifecore operates in the growing CDMO market, which is driven by increasing demand for sterile injectable pharmaceutical products and the trend of pharmaceutical companies outsourcing manufacturing activities.

Comparison to Industry Standards

• The global injectable CDMO market is estimated to be a $10B market with a +10% CAGR.
• The global CDMO market is estimated to be a $120B market with a +8% CAGR.
• Lifecore's growth strategy targets 12%+ Revenue CAGR and Adj. EBITDA margins of 25%+ in the mid-term.
• 50%+ of annual US drug approvals are injectables, indicating a strong market for Lifecore's services.

Stakeholder Impact

• Shareholders may be concerned about the net loss reported for the quarter.
• Employees may be affected by the company's efforts to reduce operational expenses and implement a performance-driven culture.
• Customers may benefit from the company's expanded capacity and capabilities.
• Suppliers may see increased demand as the company grows its business.

Next Steps

• Lifecore will continue to focus on maximizing utilization of available capacity.
• Lifecore will continue to advance programs towards commercialization.
• Lifecore will continue to drive new business.
• Lifecore will host a conference call on April 3, 2025, to discuss the company's third quarter fiscal 2025 financial results.

Key Dates

Keywords

Lifecore Biomedical, CDMO, Contract Development and Manufacturing Organization, Financial Results, Hyaluronic Acid, Adjusted EBITDA, Revenue, Net Loss, Fiscal Year 2025, Investor Presentation